Misoprostol

Study	Reference
Andersen (vs diclofenac), 2016	Andersen JT Diclofenac/misoprostol during early pregnancy and the risk of miscarriage: a Danish nationwide cohort study. Arch Gynecol Obstet 2016;294:245-50
Andersen (vs unexposed), 2016	Andersen JT Diclofenac/misoprostol during early pregnancy and the risk of miscarriage: a Danish nationwide cohort study. Arch Gynecol Obstet 2016;294:245-50
Auffret, 2016
Barbero, 2011	Barbero P [Misoprostol teratogenicity: a prospective study in Argentina]. Arch Argent Pediatr 2011;109:226-31
Brasil, 2000	Brasil R Misoprostol and congenital anomalies. Pharmacoepidemiol Drug Saf 2000;9:401-3
Dal Pizzol, 2008	Dal Pizzol Tda S Exposure to misoprostol and hormones during pregnancy and risk of congenital anomalies. Cad Saude Publica 2008;24:1447-53
Opaleye, 2010	Opaleye ES [Evaluation of the teratogenic risks in gestations exposed to misoprostol]. Rev Bras Ginecol Obstet 2010;32:19-35
Orioli, 2000	Orioli IM Epidemiological assessment of misoprostol teratogenicity. BJOG 2000;107:519-23
Pastuszak, 1998	Pastuszak AL Use of misoprostol during pregnancy and M?bius' syndrome in infants. N Engl J Med 1998;338:1881-5
Vargas, 2000	Vargas FR Prenatal exposure to misoprostol and vascular disruption defects: a case-control study. Am J Med Genet 2000;95:302-6
Vauzelle, 2013	Vauzelle C Birth defects after exposure to misoprostol in the first trimester of pregnancy: prospective follow-up study. Reprod Toxicol 2013;36:98-103